Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma.
A 73-year-old woman with metastatic transitional cell carcinoma of the bladder developed vaginal bleeding a few days after undergoing radical cystectomy. She had no other signs of mucocutaneous bleeding. Coagulation studies revealed a markedly prolonged thrombin time (greater than 600 seconds), a slightly prolonged reptilase time (20 seconds), and mildly elevated fibrinogen (4.39 g/L), and fibrin D-dimer (200 to 500 ng/mL) levels. Treatment of the patient's plasma in vitro with protamine or barium sulfate normalized the thrombin time. The anticoagulant activity corresponded to 0.15 heparin U/mL when measured by a thrombin time assay using normal plasma as substrate and standardized with porcine heparin. The anticoagulant was quantitatively bound to and subsequently eluted with 1 mol/L NaCl from quaternary aminoethyl (QAE) Sephadex, and then isolated by affinity chromatography on immobilized antithrombin III. The isolated anticoagulant was shown to be sensitive to heparinase digestion. Therefore, the inhibitor has functional and chemical properties similar to those of high-affinity heparin. Thus far, this is the only anticoagulant of this type isolated from the plasma of a patient bearing a tumor other than plasma cell myeloma.
Tefferi
A
A
Department of Biochemistry, Mayo Clinic and Foundation, Rochester, MN 55905.
Owen
B A
BA
Nichols
W L
WL
Witzig
T E
TE
Owen
W G
WG
D000368:Aged; D001777:Blood Coagulation; D002295:Carcinoma, Transitional Cell / Q000097:blood*; D005260:Female; D006493:Heparin / Q000097:blood*; D006801:Humans; D013918:Thrombin Time; D001749:Urinary Bladder Neoplasms / Q000097:blood*
D006493:Heparin